Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.
Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D. Vallerand D, et al. Among authors: savina a. PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016. PLoS One. 2016. PMID: 27388901 Free PMC article.
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R. Rodallec A, et al. Among authors: savina a. Anticancer Drugs. 2020 Jun;31(5):463-472. doi: 10.1097/CAD.0000000000000878. Anticancer Drugs. 2020. PMID: 31895102
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. Thomas G, et al. Among authors: savina a. Oncotarget. 2014 Aug 30;5(16):7138-48. doi: 10.18632/oncotarget.2231. Oncotarget. 2014. PMID: 25216528 Free PMC article.
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C. Decaup E, et al. Among authors: savina a. Front Immunol. 2019 Aug 14;10:1943. doi: 10.3389/fimmu.2019.01943. eCollection 2019. Front Immunol. 2019. PMID: 31475004 Free PMC article.
The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.
Calvayrac O, Mazières J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, Guibert N, Lusque A, Cadranel J, Mathiot N, Savina A, Pradines A, Favre G. Calvayrac O, et al. Among authors: savina a. EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm.201606646. EMBO Mol Med. 2017. PMID: 28003335 Free PMC article.
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.
Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A. Frazao A, et al. Among authors: savina a. Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2. Cancer Immunol Res. 2017. PMID: 28576831
138 results